Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Gilead Sciences, Inc.
  6. News
  7. Summary
    GILD   US3755581036

GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Nasdaq  -  04:00 2022-08-08 pm EDT
61.60 USD   +0.83%
08/08GILEAD SCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
08/05OXFORD UNIVERSITY : Oxford spinout MiroBio acquired by Gilead Sciences for $405m
AQ
08/04UBS Adjusts Gilead Sciences Price Target to $65 From $63, Maintains Neutral Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SVB Securities Initiates Gilead Sciences at Market Perform With $68 Price Target

05/23/2022 | 06:55am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about GILEAD SCIENCES, INC.
08/08GILEAD SCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
08/05OXFORD UNIVERSITY : Oxford spinout MiroBio acquired by Gilead Sciences for $405m
AQ
08/04UBS Adjusts Gilead Sciences Price Target to $65 From $63, Maintains Neutral Rating
MT
08/04Gilead Sciences to Buy UK Biotech Firm MiroBio for $405 Million
MT
08/04Gilead Sciences to Acquire MiroBio
BU
08/04Gilead Sciences, Inc. entered into a definitive agreement to acquire MiroBio Ltd from S..
CI
08/03Health Care Up After Moderna, CVS Earnings -- Health Care Roundup
DJ
08/03GLOBAL MARKETS LIVE : Airbnb, Infineon, PayPal, Moderna, Starbucks...
MS
08/03Gilead Sciences Up Over 5%, on Pace for Largest Percent Increase Since January 2021 -- ..
DJ
08/03WALL STREET STOCK EXCHANGE : A couple of hopes dashed
MS
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 25 126 M - -
Net income 2022 3 912 M - -
Net Debt 2022 15 612 M - -
P/E ratio 2022 19,5x
Yield 2022 4,73%
Capitalization 77 266 M 77 266 M -
EV / Sales 2022 3,70x
EV / Sales 2023 3,68x
Nbr of Employees 14 400
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 61,60 $
Average target price 70,35 $
Spread / Average Target 14,2%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Kevin E. Lofton Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-15.87%77 266
VERTEX PHARMACEUTICALS31.16%73 868
REGENERON PHARMACEUTICALS, INC.-2.84%65 600
BIONTECH SE-28.97%44 499
WUXI APPTEC CO., LTD.-20.64%41 093
GENMAB A/S-2.78%22 792